Oral treatment shows promise in slowing diabetic retinopathy progression

Jun 19, 2024

New Data on Oral DR Therapy

May 20, 2024

Value of Oral APX3330 for Diabetic Retinopathy Progression

May 8, 2024

APX3330 ‘promising’ oral treatment option for slowing progression of diabetic retinopathy

Feb 9, 2024

New Insight: A Look at APX3330 for Diabetic Retinopathy with George Magrath, MD

Dec 18, 2023

Oral APX3330 Receives FDA Nod for Phase 3 Endpoint in Diabetic Retinopathy

Nov 27, 2023

VIDEO: Surgeon summarizes award-winning abstract presentation on DR treatment

Aug 29, 2023

WIO 2023: ZETA-1 phase 2 trial safety and tolerability results for APX3330

Aug 26, 2023

ASRS 2023: ZETA-1 phase 2 trial efficacy results for APX3330 with David Lally, MD

Aug 9, 2023

VIDEO: Ocuphire to discuss APX3330 outcome measure with FDA

Aug 8, 2023

• 1
• 2
• 3
• 4
• 5
• 6
• Next »